Authors:
KAUFMANN IM
JONAT W
VONMINCKWITZ G
SCHMID H
KLEINE W
MELCHERT F
ULMER MU
STOSIEK U
TRAMS G
BALZER J
CAFFIER H
Citation: Im. Kaufmann et al., COMPARISON OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN/CYCLOPHOSPHAMIDE/TAMOXIFEN AND CMF-CHEMOTHERAPY VERSUS TAMOXIFEN IN NODE-POSITIVE BREAST-CANCER - AN UPDATE OF THE GERMAN ADJUVANT BREAST-CANCER GROUP (GABG) TRIAL/, European journal of cancer, 34, 1998, pp. 82-82
Authors:
VONMINCKWITZ G
KAUFMANN M
SCHMID H
KLEINE W
BRUNNERT K
ULMER MU
STOSIEK U
MAHLKE M
MEHRPOHL HG
NEISES M
BALTZER J
Citation: G. Vonminckwitz et al., RANDOMIZED TRIALS TO ASSESS THE EFFECTIVITY OF TAMOXIFEN AS ADJUVANT TREATMENT IN NODE-NEGATIVE AND RECEPTOR-POSITIVE BREAST-CANCER - THE HEIDELBERG-II AND GABG-II TRIALS, European journal of cancer, 34, 1998, pp. 96-96
Authors:
PFISTERER J
KOMMOSS F
SAUERBREI W
RENDL I
KIECHLE M
KLEINE W
PFLEIDERER A
Citation: J. Pfisterer et al., PROGNOSTIC VALUE OF DNA-PLOIDY AND S-PHASE FRACTION IN STAGE-I ENDOMETRIAL CARCINOMA, Gynecologic oncology, 58(2), 1995, pp. 149-156
Authors:
GIESE E
KLEINE W
SAUERBREI W
PFLEIDERER A
Citation: E. Giese et al., SIGNIFICANCE OF A NEW CLASSIFICATION-SYST EM FOR ENDOMETRIAL CANCER (FIGO 1988), Archives of gynecology and obstetrics, 254(1-4), 1993, pp. 977-979